NAMS – newamsterdam pharma company n.v. - ordinary shares (US:NASDAQ)
Stock Stats
News
NewAmsterdam Pharma (NASDAQ: NAMS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $36.00 price target on the stock.
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Form 10-Q NewAmsterdam Pharma Co For: Sep 30
Form 8-K NewAmsterdam Pharma Co For: Nov 06
Form 20-F/A NewAmsterdam Pharma Co For: Dec 31
Form 8-K NewAmsterdam Pharma Co For: Oct 18
Form 4 NewAmsterdam Pharma Co For: Oct 09 Filed by: Davidson Michael H.
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.